SCHEMBL24011500

SCHEMBL24011500

CC(C)(O)CN1CCN(C(=O)C2CCC(NC(=O)NCc3ccc(Cl)cc3)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 3/20 0.53
▸ DRD4 P21917 1/20 0.45
▸ MCHR1 Q99705 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24011707 1.00 EPHX1 (0.53) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL24011708 1.00 EPHX1 (0.53) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL24011394 0.90 MCHR1 (0.52) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL26764306 0.89 EPHX1 (0.46) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL26764199 0.89 EPHX1 (0.46) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL24011390 0.89 SMN1; SMN2 (0.56) DRD4MCHR1SMN1; SMN2RAB9AHRH3
SCHEMBL24011373 0.87 EPHX1 (0.51) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL24011381 0.84 EPHX1 (0.57) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL26633918 0.79 EPHX1 (0.44) EPHX1DRD4MCHR1SMN1; SMN2RAB9A
SCHEMBL24011709 0.79 KMT2A (0.41) L3MBTL1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT EPHX1 3913/4885DRD4 3923/4885MCHR1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback